The development of antiviral drugs (nucleoside analoguse) during the past 15 years has been the most important advance in the treatment of HSV (Whitley,1996). These drugs disrupt the viral replication by interfering with DNA synthesis in the HSV infected cell. Activation of the virus-specific enzyme thymidine kinase (TK) by the host cell further enhances the drug entry into the infected cell